AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00929344 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized behavioral therapy
Description: Standardized behavioral therapy 1 time per week for 12 week duration.
Study NCT03298997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligation and Hemorrhoidopexy
Description: Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to pudendal nerve block.
Study NCT03298997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Ligation of Hemorrhoidal Arteries
Description: Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to spinal anesthesia.
Study NCT03068689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is > 185mm HG the cuffs are inflated to 15 mmHG above that level.
Study NCT03068689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01242241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
Study NCT01242241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
Study NCT04338477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nephrosolid tablets
Description: Adminstration of drug
Study NCT01853293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kudzu extract
Study NCT01853293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01853293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
Study NCT01853293 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medical Management
Description: Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
Study NCT00109746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chromium picolinate
Description: HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
Study NCT02260206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
Study NCT02600611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iclaprim
Description: Experimental treatment
Study NCT02600611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: Active comparator
Study NCT04173416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Opioid Recovery Support (YORS)
Description: The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
Study NCT00384202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppression
Study NCT03134729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine for Serratus Plane Block (SPB)
Description: Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
Study NCT02954549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: As in Arms
Study NCT02954549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: As in Arms
Study NCT02155985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
Study NCT02155985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for aspirin
Study NCT02155985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for aspirin
Study NCT02998151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: two 666mg pills
Study NCT02998151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: two 20mg pills
Study NCT02998151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: two 135mg pills
Study NCT02998151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo pill
Study NCT02998151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: one 30mg pill
Study NCT00870467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double-blind adalimumab
Description: Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
Study NCT00870467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-blind Placebo
Description: Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
Study NCT00870467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-blind Placebo
Description: Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
Study NCT00870467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-label Adalimumab
Description: Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
Study NCT00870467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-labelAdalimumabRescue
Description: Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
Study NCT01361828 — intervention group
Intervention type: PROCEDURE
Intervention: Electrophysiology
Description: Visual Evoked Potential and Elctroretinogram
Study NCT02740959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Polysaccharides 500 mg
Description: PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
Study NCT02740959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Polysaccharides 250 mg
Description: PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
Study NCT03199950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol 2dd1mg (08.00am - 10.00pm)
Study NCT03199950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral 2dd (08.00am - 10.00pm)
Study NCT01325545 — intervention group
Intervention type: OTHER
Intervention: Mobile cardiac rhythm monitoring
Description: Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
Study NCT02340143 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Marketed partially hydrolyzed cow's milk protein infant formula
Study NCT02340143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational
Description: Partially hydrolyzed cow's milk protein infant formula with a probiotic
Study NCT05291130 — intervention group
Intervention type: DEVICE
Intervention: Plasmafit® Vitelene® Vitamin E
Description: Plasmafit® Acetabular Cup System with an insert Aesculap ® Vitelene ® Vitamin E Stabilized Highly Crosslinked Polyethylene and BIOLOX delta Ceramic Femoral Head or ISODUR® Metal Femoral Heads
Study NCT03113110 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin 10 mg
Description: PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
Study NCT04273516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily
Study NCT04273516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivaroxaban placebo tablets
Description: Placebo tablets add to ASA 80 mg daily that is standard treatment
Study NCT04506723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Nephrolithotomy
Description: PCNL will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
Study NCT04506723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial nephrectomy
Description: Partial nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
Study NCT04506723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical nephrectomy
Description: Nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
Study NCT03518086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV
Study NCT03518086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02258594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Patient Centered Toolkit (PCTK)
Description: The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread.
Study NCT02258594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Patient-SatisfActive® Model
Description: The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
Study NCT01878318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: stable dose
Study NCT01878318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks, 24 weeks
Study NCT03827694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-Invasive Testing for PIFI
Description: galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq
Study NCT03758599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Climbing
Description: All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
Study NCT03758599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
Study NCT03758599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Social Contact
Description: All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
Study NCT03932461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum assisted closure
Description: The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.
Study NCT03932461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Relaparotomy on demand
Description: Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.
Study NCT06611904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Combined treatment with dulaglutide and dapagliflozin
Study NCT06611904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 Inhibitors
Description: DPP-4i treatment as an add-on to metformin
Study NCT01989013 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: biweekly intervention
Description: 10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
Study NCT03414242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical spine musculature
Description: Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
Study NCT02155452 — intervention group
Intervention type: PROCEDURE
Intervention: ALA
Description: Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation
Study NCT04784507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En Bloc Resection
Description: En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)
Study NCT04784507 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
Description: Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
Study NCT03416192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MCO-HD
Description: Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.
Study NCT03416192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCO-HD
Description: Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.
Study NCT03416192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flux HDF
Description: Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
Study NCT03416192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flux HDF
Description: Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
Study NCT01461733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amiodarone
Description: standard dose amiodarone
Study NCT01461733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo delivered blinded
Study NCT00570960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextran 70
Description: dextran 70, 1.0 g/kg on days one, two and three
Study NCT00570960 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human albumin
Description: human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
Study NCT04367662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: blood sampling in hospitalized patient for COVID-19 infection
Study NCT03020628 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Description: For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
Study NCT03020628 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NBP607-TIV
Description: For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
Study NCT04017715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: warm up
Description: Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition